Western blot analysis revealed that ArcA treatment led to a marked reduction in the levels of phosphorylated GSK-3β (p-GSK-3β) at Ser9 across all four melanoma cell lines (Fig. 3E, F). The gene discussed is GSK3B; the disease is melanoma.